Citigroup upgraded Nevro from Sell to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | $4.50 → $5.85 | Underperform → Hold | Jefferies |
| 2/7/2025 | $6.00 → $5.85 | Neutral → Overweight | Piper Sandler |
| 12/3/2024 | $5.00 | Equal Weight | Wells Fargo |
| 12/2/2024 | $9.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 8/9/2024 | Sell → Neutral | Citigroup | |
| 8/8/2024 | Underperform → Peer Perform | Wolfe Research | |
| 8/7/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/7/2024 | Neutral → Underweight | JP Morgan |
15-12G - NEVRO CORP (0001444380) (Filer)
EFFECT - NEVRO CORP (0001444380) (Filer)
SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)